EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown

Edmund Ingham Investing Group Leader Follow Summary Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort. EYPT's management argues the failure was driven by nine patients (4%) with vision loss unrelated to wet AMD, and highlights strong secondary endpoints and durability advantages. Upcoming LUCIA Phase 3 data in Q4 2026 is pivotal; a positive result could revive the Duravyu program and restore investor confidence. I rate EYPT a speculative buy, recognizing both the significant upside if LUCIA succeeds and the high risk given financial pressures and a crowded competitive landscape. This idea was discussed in more depth with members of my private investing community, Haggerston BioHealth. Learn More » bunhill/E+ via Getty Images Investment Overview The stock of Eyepoint Pharmaceuticals ( EYPT ) crashed in value from ~$15 per share, to <$4.5 on Monday - down ~70% - after the eye disease specialist reported top-line data from its LUGANO pivotal Phase 3 study of lead candidate Duravyu (vorolanib This article was written by Edmund Ingham 15.11K Followers Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in EYPT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.